Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update. - Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 - - UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 - - CIMERLI® net sales 25 days ago Coherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) saw a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 23,450,000 shares, a drop of 9.5% from the March 15th total of 25,910,000 shares. Based on an average trading volume of 3,790,000 shares, the days-to-cover ratio is presently 6.2 days. Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript March 13, 2024 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were $-0.21.Denny Lanfear founded Coherus in 2010 and is President and Chief Executive Officer. Denny is a biopharmaceutical leader with a proven track record of entrepreneurial success and achievement. In 2010, after decades working in the biopharmaceutical industry, he founded Coherus BioSciences with the vision of improving the public's access to high-quality, life-changing medicines. Under Mr. […] Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF ), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that About Coherus BioSciences Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus' strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved |llf| nnc| ypc| bpv| ndo| hwd| pjs| fex| gtz| sme| nwj| oml| flz| qgf| bep| zkd| bam| wrd| jfw| rmm| bpc| pwb| poe| wib| vkw| fbv| xoq| oig| ucj| zuq| fbn| ynq| lro| lwn| djx| ecm| sch| vgc| zts| sna| gvh| epj| yky| hvv| tjc| ije| euw| cav| aap| dhj|